EX-99.1 2 txg-20240808xexx991.htm EX-99.1 Document

Exhibit 99.1
a10x_logoxhorizontalxfullcb.jpg
10x Genomics Reports Second Quarter 2024 Financial Results
PLEASANTON, Calif. August 8, 2024 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2024.
Recent Highlights
•Revenue was $153.1 million for the second quarter, a 4% increase over the corresponding period of 2023, primarily driven by stronger contributions from consumables.
•Began shipping Xenium Prime 5K, which measures 5,000 genes and features an enhanced chemistry to deliver excellent per-gene sensitivity, improved specificity and spatial fidelity, and integrated multimodal cell segmentation.
•Announced that the Garvan Institute of Medical Research selected Chromium GEM-X for its new TenK10K project, which intends to map 50 million human cells to identify unique genomic fingerprints of autoimmune diseases, heart diseases and cancer.
“While it’s a challenging macro environment, we saw strong demand for spatial and single cell consumables this quarter, fueled by significant product launches earlier this year,” said Serge Saxonov, Co-founder and CEO of 10x Genomics. “We remain confident in the strength, differentiation and long-term potential of our platforms as we evolve our commercial organization and continue to execute our strategy.”
Second Quarter 2024 Financial Results
Revenue was $153.1 million for the second quarter of 2024, a 4% increase from $146.8 million for the corresponding prior year period.
Gross margin was flat year over year at 68%.
Operating expenses were $146.0 million for the second quarter of 2024, a 10% decrease from $163.0 million for the corresponding prior year period. This decrease was primarily driven by lower personnel expenses, including stock-based compensation expense, and a decrease in laboratory materials and supplies.
Operating loss was $41.7 million for the second quarter of 2024, as compared to $63.4 million for the corresponding prior year period. Operating loss includes $38.5 million of stock-based compensation for the second quarter of 2024, as compared to $45.7 million of stock-based compensation for the corresponding prior year period.
Net loss was $37.9 million for the second quarter of 2024, as compared to a net loss of $62.4 million for the corresponding prior year period.
Cash and cash equivalents and marketable securities were $380.1 million as of June 30, 2024.
2024 Financial Guidance
10x Genomics is updating its outlook for the full year 2024. The company now expects revenue to be in the range of $640 million to $660 million versus a prior range of $670 million to $690 million. The updated range represents 3% to 7% growth over full year 2023 revenue.
Webcast and Conference Call Information
10x Genomics will host a conference call to discuss the second quarter 2024 financial results, business developments and outlook after market close on Thursday, August 8 , 2024 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the
1
a10x_logoxhorizontalxfullcb.jpg
conference call can be accessed at http://investors.10xgenomics.com. The webcast will be archived and available for replay at least 45 days after the event.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world’s understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s product momentum, potential, organization, strategy, demand, progress and launches, our expected performance advantages and benefits of using our products and services, customer usage and adoption of our products and our financial performance and results of operations, including our expectations regarding revenue and guidance. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K for the fiscal year ended December 31, 2023 and the company’s 10-Q for the quarter ended March 31, 2024 to be filed with the Securities and Exchange Commission (SEC) and elsewhere in the documents 10x Genomics, Inc. files with the SEC from time to time.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.


Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
2
a10x_logoxhorizontalxfullcb.jpg
10x Genomics, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share data)
Three Months Ended
June 30,		Six Months Ended
June 30,
2024202320242023
Revenue (1)
$153,104 $146,819 $294,110 $281,104 
Cost of revenue (2)
48,884 47,207 96,976 83,102 
Gross profit104,220 99,612 197,134 198,002 
Operating expenses:
Research and development (2)
62,918 71,460 131,556 138,558 
Selling, general and administrative (2)
83,039 91,510 168,813 174,790 
Total operating expenses145,957 162,970 300,369 313,348 
Loss from operations(41,737)(63,358)(103,235)(115,346)
Other income (expense):
Interest income4,715 4,100 9,451 7,969 
Interest expense(1)(5)(2)(24)
Other expense, net(56)(1,504)(1,096)(3,020)
Total other income4,658 2,591 8,353 4,925 
Loss before provision for income taxes(37,079)(60,767)(94,882)(110,421)
Provision for income taxes818 1,647 2,964 2,740 
Net loss$(37,897)$(62,414)$(97,846)$(113,161)
Net loss per share, basic and diluted$(0.32)$(0.53)$(0.82)$(0.97)
Weighted-average shares of common stock used in computing net loss per share, basic and diluted120,066,972 116,707,672 119,461,485 116,166,776 

3
a10x_logoxhorizontalxfullcb.jpg
(1)The following table represents revenue by source for the periods indicated (in thousands). Spatial products includes the Company’s Visium and Xenium products:
Three Months Ended
June 30,		Six Months Ended
June 30,
2024202320242023
Instruments
Chromium$8,792 $12,859 $16,642 $24,485 
Spatial15,060 18,096 32,663 25,646 
Total instruments revenue23,852 30,955 49,305 50,131 
Consumables
Chromium94,108 100,794 178,035 201,890 
Spatial29,254 11,694 55,662 22,976 
Total consumables revenue123,362 112,488 233,697 224,866 
Services5,890 3,376 11,108 6,107 
Total revenue$153,104 $146,819 $294,110 $281,104 
The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2024202320242023
Americas
United States$89,672 $88,394 $165,309 $164,675 
Americas (excluding United States)3,419 3,149 7,412 5,664 
Total Americas93,091 91,543 172,721 170,339 
Europe, Middle East and Africa37,362 31,246 72,083 59,668 
Asia-Pacific
China13,738 12,755 27,662 26,786 
Asia-Pacific (excluding China)8,913 11,275 21,644 24,311 
Total Asia-Pacific22,651 24,030 49,306 51,097 
Total Revenue$153,104 $146,819 $294,110 $281,104 
(2)Includes stock-based compensation expense as follows:
Three Months Ended
June 30,		Six Months Ended
June 30,
(in thousands)
2024202320242023
Cost of revenue$2,247 $1,835 $4,280 $3,296 
Research and development17,862 19,560 34,750 37,340 
Selling, general and administrative18,383 24,301 35,591 47,161 
Total stock-based compensation expense$38,492 $45,696 $74,621 $87,797 
4
a10x_logoxhorizontalxfullcb.jpg
10x Genomics, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands)
June 30,
2024		December 31,
2023
Assets
Current assets:
Cash and cash equivalents$379,824 $359,284 
Marketable securities269 29,411 
Accounts receivable, net91,178 114,832 
Inventory88,272 73,706 
Prepaid expenses and other current assets19,612 18,789 
Total current assets579,155 596,022 
Property and equipment, net263,285 279,571 
Operating lease right-of-use assets60,872 65,361 
Goodwill4,511 4,511 
Intangible assets, net16,658 16,616 
Other noncurrent assets5,187 3,062 
Total assets$929,668 $965,143 
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$21,248 $15,738 
Accrued compensation and related benefits20,078 30,105 
Accrued expenses and other current liabilities42,437 56,648 
Deferred revenue16,436 13,150 
Operating lease liabilities10,820 11,521 
Total current liabilities111,019 127,162 
Operating lease liabilities, noncurrent78,662 83,849 
Deferred revenue, noncurrent11,358 8,814 
Other noncurrent liabilities4,571 4,275 
Total liabilities205,610 224,100 
Commitments and contingencies
Stockholders’ equity:
Preferred stock— — 
Common stock2 2 
Additional paid-in capital2,106,752 2,025,890 
Accumulated deficit(1,382,266)(1,284,420)
Accumulated other comprehensive loss(430)(429)
Total stockholders’ equity724,058 741,043 
Total liabilities and stockholders’ equity$929,668 $965,143 
5